Very Low Birth Weight Infants Clinical Trial
Official title:
Oropharyngeal Colostrum for Immune Stimulation in Very Low Birth Weight Infants
Colostrum, mothers' early breastmilk, contains multiple factors that provide immune protection to very low birth weight (VLBW) infants, a population at high risk for hospital-acquired infections. However, critical illness during the first few days of life often prevents the initiation of enteral feeds, placing these infants at even higher risk for morbidities including feeding intolerance and infection. Oropharyngeal administration has been proposed as an alternative route of delivery for colostrum and the immune benefits it provides. Research from animal and adult human models supports oropharyngeal administration as a potentially safe and effective mode of delivery for immune therapies. Immune components of colostrum, such as secretory IgA, may have both direct and indirect effects on the immune system. The purpose of this proposed randomized, placebo-controlled pilot study is to determine the effect of oropharyngeally administered colostrum (OAC) on immune stimulation in VLBW infants, as measured by secretory IgA (sIgA) levels. In addition to measuring sIgA response to OAC the investigators will also collect clinical data to determine if OAC has effects on tolerance of enteral feedings and rates of infection. The investigators hypothesize OAC will have a moderate effect on salivary secretory IgA concentration in VLBW infants. If proven efficacious, utilization of OAC in VLBW infants could have far reaching consequences for these highly fragile babies including lower rates of infection, improved tolerance of enteral feedings, and shorter NICU stays.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00033917 -
Indomethacin Germinal Matrix Hemorrhage/Intraventricular Hemorrhage (GMH/IVH) Prevention Trial
|
Phase 3 | |
| Completed |
NCT02741934 -
Cognitive and Behavioral Outcomes of School-aged Children Who Were Born Preterm
|
N/A | |
| Withdrawn |
NCT00470743 -
Comparing Ibuprofen And Indomethacin For The Treatment Of The Patent Ductus Arteriosus in Very Premature Babies
|
Phase 4 | |
| Completed |
NCT02415530 -
Early Family Based Intervention in Preterm Infants
|
N/A | |
| Completed |
NCT01531192 -
Comparison of Lactobacillus Reuteri and Nystatin Prophylaxis on Candida Colonization and Infection in Very Low Birth Weight Infants
|
Phase 4 | |
| Withdrawn |
NCT03858816 -
Efficacy of Multiple Strain Probiotics Reduces the Neurobehavioral Disorder in Premature Very Low Birth Weight Infants
|
N/A | |
| Terminated |
NCT01434849 -
Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial)
|
Phase 1 | |
| Recruiting |
NCT03876704 -
Effects of Fat-soluble Vitamins Supplementation on Common Complications and Neural Development in Very Low Birth Weight Infants
|
Phase 3 | |
| Completed |
NCT02383264 -
Splanchnic Oxygenation After the First Enteral Feed in Preterm Infants: Prediction of Feeding Tolerance.
|
N/A | |
| Completed |
NCT01531179 -
Lactobacillus Reuteri for Prevention of Necrotizing Enterocolitis in Very Low-birth Weight Infants
|
Phase 3 | |
| Recruiting |
NCT01315821 -
Effect of Saccharomyces Boulardii on Necrotizing Enterocolitis in Very Low Birth Weight Infants
|
Phase 3 | |
| Withdrawn |
NCT00425581 -
N-Terminal Pro-B-Type Natriuretic Peptide and Troponin Levels as Markers of Hemodynamic Stability in Very Low Birth Weight Infants During the First Days of Life
|
N/A | |
| Completed |
NCT01287507 -
Lactoferrin Prophylaxis in VLBW and Regulator T-cells
|
N/A | |
| Recruiting |
NCT02731092 -
Safety and Tolerability of Lactoferrin in Very Low Birth Weight Infants
|
Phase 1 | |
| Terminated |
NCT02337088 -
Delayed Cord Clamping in Very Low Birth Weight Infants
|
N/A |